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Amphetamine (2.0 mg/kg) produce hypo-activity around hour 20 postadministration in rat (White, Feldon & White, 2004). The hypo-activity may be an
a pect of acute withdrawal, because other indications of withdrawal a.re present at the
same time, including REM sleep rebound, unwill ingne

to work for reward, and a

Haloperidol cue state (Barr & Phillips, 1999; Barrett, White & Caul, 1992; Edgar &
Seidel, 1997). The purpo e of the e studies was to investigate the dopaminergic
mechanisms involved in producing amphetamine-induced hypo-activity. More
specifical ly, the goal was to study the contribution of different dopamine receptor
subtypes to the phenomenon.

In order to pursue this objective two experiment were conducted. In both
experiments, male Wistar rats were individually housed in plastic cubicles, where
they were on a 12-12 hr light-dark cycle and had free acces to food and water. A
camera mounted above each cubicle was connected to a computer by a multiplexer.
Tracking software used camera images to quantify activity in terms of total distance
moved per hour. Different group of rat were given subcutaneous administration of
different doses of SKF 81297 (SKF), a dopanu ne 01 receptor agonist, or of

Quinpirole, a dopamine D2 receptor agonist. In Experiment 1 different groups of rats
were given administrations of saline, 2.0 mg/kg amphetamine, 0.2 mg/kg SKF, 0.4
mg/kg SKF, 0.2 mg/kg Quinpirole, or 0.4 mg/kg Quinpirole. In Experiment 2
different groups of rats were given combined administrations of 0.0 SKF/ 0.4
Quinpirole, 0.2 SKF/ 0.4 Quinpirole, 0.4 SKF/ 0.4 Quinpirole or 0.8 SKF/ 0.4
Quinpirole. All treatments occurred at the start of the light period and were separated
by at least a 48-hr interval. Activity was monitored for 33 hr after each treatment.
In Experiment 1 only amphetamine produced hypo-activity 20 hr post-

administration. Selective stimulation of D 1 or D2 receptors was not sufficient to
produce such hypo-activity. In Experiment 2 the two higher dose combinations (0.4
SKF/ 0.4 Quinpirole and 0.8 SKF/ 0.4 Quinpirole) produced hypo-activity 20 hr postadministration. The lower dose combinations did not.
Combined stimulation of D l and D2 receptors above a threshold level by
amphetamine may be sufficient to initiate amphetamine-induced hypo-activity. This
raises the possibility that the cascade of events by which amphetamine produces other
indications of acute withdrawal is also initiated by the short term activation of D l and
D2 receptors. The methods used here may provide a convenient animal model with
which to further study the determinants of amphetamine-induced hypo-activity and
acute withdrawal.
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Dopamine Dl and D2 Receptor Interaction
May Initiate Amphetamine-Induced Hypo-Activity in Rats
Research has shown that certain doses of amphetamine can cause hypoactivity 20 hr post-treatment in rats (White, Feldon & White, 2004). The objective of
the current research was to evaluate whether certain dopaminergic mechanisms might
have contributed to this amphetamine-induced hypo-activity.
In order to pursue this objective, different groups of rats were given different
doses of SKF 81297, a DI-like receptor agonist, or of Quinpirole, a D2-like receptor
agonist; or they received doses of the agonists combined. Effects on activity were
evaluated by housing rats in individual stations where activity was continuously
monitored. If a particular treatment had the ability to produce hypo-activity, then the
specific mechanism affected might also be involved in amphetamine's ability to
induce hypo-activity.
In the remainder of this introduction I will do the following. I. will describe
some of amphetamine's immediate effects in humans. Because I am focusing on
activity, I will then describe amphetamine's immediate and longer-term effects on
activity and on other measures in rats. Amphetamine has several time-dependent
effects, so I will introduce a terminological distinction that clarifies what I am trying
to account for. Amphetamine affects multiple neurotransmitters, so I will describe
evidence that justifies the focus on dopamine (DA). I will then review dopaminergic
mechanisms, with a focus on dopamine pathways and the structure and function of
the dopamine receptor subtypes. Then, I will explain why activity is a good
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behavioral measure. Finally, I will talk about specific goals and hypotheses and
conclude with the significance of this research.

Immediate effects in humans. The immediate effects of amphetamine in
humans are well known (reviewed in Julien, 2004; Segal & Kuczenski, 1994). During
the first several hours post-administration, amphetamine produces signs of autonomic
arousal including an increase in blood pressure, heart rate, respiration, metabolism,
and body temperature, as well as dilatation of the pupils. Amphetamine also produces
signs of cognitive, motivational, and emotional arousal including an increase in
alertness, increased energy, and a feeling of well-being and euphoria (Julien, 2004).

Immediate and longer-tenn effects in rats. The immediate effects of
amphetamine on the activity of rats are dose-dependent. A moderate dose of 1.0
mg/kg produces an increase in locomotor activity and rearing, as well as mild sniffing
and head bobbing. A moderately high dose of 2.0 mg/kg produces an increase in
locomotor activity intermixed with low gauge stereotypy. A high dose of 4.0 mg/kg
produces a multi-phasic pattern: An initial increase in locomotion is replaced by
intense stereotypy which is then followed by another increase in locomotion
(reviewed in Feldman, Meyer & Quenzer, 1997).
Additional immediate effects of amphetamine in rats include autonomic
changes. Drug discrimination, conditioned place preference, and drug selfadministration studies indicate that amphetamine produces discriminable internal
cues, some of which are rewarding (reviewed in Hoffman, 1989).
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Amphetamine also has some longer term effects on activity. White et al.
(2004) found that male Sprague-Dawley rats, when given 1.0 mg/kg amphetamine,
were hypo-active around hours 19-21 post-treatment. White and White (in press) gave
male Wistar rats a range of amphetamine doses (1.0 mg/kg, 2.0 mg/kg and 4.0
mg/kg). They found that the 1.0 mg/kg dose did not produce hypo-activity around
hour 20 post-treatment but that the 2.0 and 4.0 mg/kg doses did.
In addition to immediate effects and effects 20 hr after adntinistration,
amphetantine and other psychomotor stimulants enhance activity and autonontic
function for several hours beginning approximately 24 hr after adntinistration
(Tomatzky & Miczek, 1999; White et al., 2004; White & White, in press). The
changes may indicate a recovery state.

Induction and expression. Amphetamine is followed by different effects at
different times. Therefore, it is useful to introduce new terntinology in order to clarify
my interest. 'Induction' will be used to refer to the events that must occur in the short
term to produce the hypo-activity near hour 20. 'Expression' will be used to refer to
the events involved in the manifestation of the hypo-activity. I am interested in
investigating what form of short-term dopantinergic stimulation is sufficient to
produce hypo-activity 20 hr later, therefore, I am interested in the process of
induction.
The purpose of this research was not to investigate how induction and
expression ntight be linked. However, the opponent process theory (Solomon &
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Corbit, 1974) and the distinction between within and between system adaptations
(Koob & Bloom, 1988) explain how induction and expression could be linked.
According to opponent process theory, intense states are followed later by a
rebound in the opposite direction (Solomon & Corbit, 1974). The opponent process
theory of drug addiction describes how the withdrawal from a drug can promote drug
dependence and addiction through negative reinforcement (Barr, Markou & Phillips,
2002). Thus, an individual will try to restore hedonic equilibrium by self medication
through drug intake.
A within-system adaptation produces a rebound when "the primary cellular
response responsible for the acute hedonic effects of the drug would itself adapt to
oppose and neutralize the drug's effects; persistence of the opposing effects after the
drug disappears would produce the motivational withdrawal response." A betweensystems adaptation produces a rebound when "cellular and molecular systems
different from those responsible for the acute hedonic effects of the drug, triggered by
the changes in the primary drug response neurons, would contribute to or produce the
motivational effects of withdrawal after drug removal (Koob & Bloom, 1988)." In
other words, in a within-system adaptation, the same mechanisms that are involved in
induction are also involved in expression. Alternatively, in a between-systems
adaptation, different mechanisms are involved in induction and expression. How
these processes might be applicable to this research will be discussed in more detail
later.
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Justification for dopamine involvement. Amphetamine is

an indirect agonist of

catecholamines, including dopamine, norepinephrine and serotonin. For example,
amphetamine promotes the release of dopamine from the presynapse, and it blocks
reuptake of dopamine and norepinephrine and serotonin. Amphetamine can also
inhibit the storage of dopamine in vesicles and inhibit the destruction of dopamine by
enzymes (Julien, 2004). The stimulation of one or more catecholaminergic receptors
in the short-term by amphetamine would appear to be involved in induction.
I focused on dopamine because non-selective stimulation of dopaminergic
receptors in the short-term appears to produce hypo-activity near hour 20.
Apomorphine is a non-selective direct agonist of dopamine. White, Mattingly, Duke,
Liu, Dunkman, Charles, and White (2002) gave male Wistar rats 1.0 mg/kg or 2.0
mg/kg apomorphine and found that the rats were hypo-active 19-21 hr post-treatment.
This time course parallels the time course seen with amphetamine. The study suggests
that amphetamine's ability to produce hypo-activity might be mediated via dopamine
receptors.
Other research has suggested that dopamine might be involved in the
expression of hypo-activity. Barrett, White, and Caul (1992), Persico, Schindler,
Zaczek, Brannock, and Uhl (1995), and Tonge (1974) have all found molecular and
neurochemical changes in dopamine 20 hr after amphetamine treatment that might be
related.
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Because research has established that dopamine is involved in amphetamineinduced hypo-activity, it becomes reasonable to investigate the specific dopaminergic
mechanism/s that might underlie the phenomenon.

Review of dopaminergic mechanisms. Dopamine is a main neurotransmitter
that has an important role in the control of motor activity, reward-related
mechanisms, and emotional and cognitive processes. The dopaminergic system
includes several pathways. The main dopaminergic pathways in the brain are the
nigrostriatal, mesolimbic, and mesocortical. The nigrostriatal pathway projects from
the substantia nigra to the striatum. The mesolimbic pathway projects from the vental
tegmental area (VTA) to the nucleus accumbens, olfactory tubercle, septum, and
amygdala. Finally, the mesocortical pathway projects from the VTA to the prefrontal
cortex (Julien, 2004; Wishaw, Kolb & Wishaw, 2003).
Five dopamine receptor sub-types have been identified on the basis of
structural, pharmacological, and functional characteristics. The DI and D5 subtypes
are categorized under the DI-like family and the D2, D3 and D4 subtypes are
categorized under the D2-like family. In these studies I will use pharmacological
agents to selectively stimulate the two main dopamine receptors, the DI and D2
receptors. After I review the molecular structure, the localization and the functions of
the DI receptor, I will do the same for the D2 receptor.
The DI-like receptors are seven transmembrane domain metabotrophic
receptors. Structurally the DI-like receptor has the N-terminus localized on the
extracellular surface, a long C-terminus which projects into the cytosol, and a small
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third cytoplasmic loop. DI-like receptors are found in the hypothalamus, thalamus,
ofactory tubercle, substantia nigra pars reticulata, striatum and nucleus accumbens.
DI-like receptors are found primarily at the post-synapse (Sibley, Monsuma & Shen,
1993).
DI-like receptor activation has been found to increase motor activity. Dl
receptor stimulation with agonists elicits locomotion, grooming and rearing in rats
(Molloy & Wadington, 1984). Direct infusion of D 1 agonist into the dorsal striatum
or nucleus accumbens elicits hyperactivity and the development of behavioral
sensitization to the locomotor-activating effects of amphetamine. Furthermore, Dl
agonist infusion into the nucleus accumbens produces a conditioned place preference
and supports drug discrimination, whereas Dl anatagonists attenuate these effects
(Waddington, 1986).
The D2-like receptor is also a seven transmembrane domain metabotrophic
receptor. However, structurally the D2-like receptor differs from the DI-like receptor
because its C-terminus is small and its third cytoplasmic loop is large. D2-like
receptors are found in the ventral tegmental area, granule area of the hippocampal
formation, substantia nigra pars compata, septal region, cingulate, nucleus
accumbens, amygdala and prefrontal region. D2-like receptors are found at both the
pre- and post-synapse (Sibley et al., 1993).
D2-like receptor stimulation has been found to increase locomotion, sniffing
and snout contact (Eilam, Golani & Szechtman, 1989; Molloy & Waddington, 1985;
Walters, Bergstrom, Carlson, Chase & Braun, 1987). D2 agonists do not produce a
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conditioned place preference but do produce a discriminative stimulus effect (Nielsen
& Scheel-Krueger, 1986). D2 receptor stimulation has been found to produce
behavioral effects similar to those of non-selective dopamine agonists.

Activity as the dependent variable. The main dependent variable m this
research was an activity measure. An activity measure has several advantages. First,
the rat circadian activity pattern is well understood: Activity occurs in bouts that are
separated by one to several hours, and most activity occurs during the dark period.
Second, the effects of drugs on activity can be easily identified against this well
known background. Finally, changes in activity can be used to make inferences about
the drug-induced state that an animal is in.

Goals and hypothesis. The purpose of this research was to investigate which
dopaminergic receptors produce amphetamine-induced hypo-activity. Specifically:
•

In Experiment 1, activity was measured following one of several

treatments. Treatments included administration of amphetamine,
saline, and different doses of either dopamine DI receptor agonist
(SKF 81297) or dopamine D2 receptor agonist (Quinpirole).
•

In Experiment 2, activity was measured following one of several

treatments. Treatments included administration of different doses of
D1 receptor agonist (SKF 81297) combined with D2 receptor agonist
(Quinpirole).
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The ability either of a selective agonist or of the agonists in combination to
produce hypo-activity would indicate. which specific dopaminergic receptors are
involved in amphetamine-induced hypo-activity.
Significance and implications. The longer-term effects of amphetamine need

to be studied for various reasons. Acute administration of psychostimulants is not
thought to produce symptoms of hangover. However, the presence of hypo-activity
20 hr post-amphetamine administration suggests that there may be costs to even acute
amphetamine use. Longer term motivational processes might be affected by
amphetamine. In particular, amphetamine-induced hypo-activity may compete with
psychological processes necessary for effective task performance. Amphetamineinduced hypo-activity may even be an indicator of an acute withdrawal syndrome.
This research may help us identify novel side effects produced by amphetamine
administration.
Additionally, this research may promote the development of an animal model
of amphetamine-induced acute withdrawal. We eventually want to use such a model
to understand the mechanisms underlying different symptoms of acute withdrawal.
Information regarding the symptoms present during amphetamine-induced acute
withdrawal in humans has not been obtained, primarily because human drug use
occurs under very complex circumstances. Inducing these symptoms in humans under
controlled circumstances would not be ethical. Hence, it is necessary to use an animal
model approach. Understanding the psychological processes and identifying the
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mechanisms that contribute to amphetamine-induced hypo-activity and acute
withdrawal may help us identify potential treatments for amphetamine abuse.
Experiment 1: Selective Dopamine Receptor Activation
Treatment with either amphetamine or apomorphine produces hypo-activity
20 hr later, suggesting that the hypo-activity may be dependent on short term
stimulation of dopaminergic receptors. Apomorphine is a nonselective dopamine
agonist: It activates both DI and D2 receptors. Consequently, whether apomorphine
(and by inference, amphetamine) produces hypo-activity by activating the DI
receptor subtype, the D2 receptor subtype, or both is uncertain. Experiment I
investigated whether hypo-activity 20 hr after treatment could be elicited by
stimulating either DI or D2 receptor subtypes alone.
To justify my methods, I will briefly review the dopamine agonists that I used.
First, I will review SKF 81297, a selective direct DI-like agonist. Then I will review
Quinpirole, a selective direct D2-like agonist. Because I am measuring activity, I will
describe how the drugs affect immediate activity and why they might result in hypoactivity in the longer-term. Finally, I will identify neural structures that may be
involved in the agonist-induced behaviors.
Hypotheses.

•

Selective dopamine DI receptor activation with the agonist SKF
81297 would produce hypo-activity 20 hr post-treatment.

•

Selective dopamine D2 receptor activation with the agonist Quinpirole
would produce hypo-activity 20 hr post-treatment.

If either selective agonist (SKF 81297 or Quinpirole) produced hypo-activity
20 hr later, then amphetamine might do the same via a similar mechanism.

DJ-like agonist: SKF 81297. SKF 81297 (SKF) is a full dopamine DI-like
receptor agonist. The agonist is a benzazepine derivative. Andersen and Jansen
( 1990) showed, with a measure of adenylate cyclase stimulation, that SKF has a very
high affinity for DI receptors.
A number of studies have shown the immediate effects of SKF 81297 on
activity in rats (Alleweireldt, Weber, Kirschner, Bullock & Neisewander, 2002; Arnt,
Hyttel & Sanchez, 1992; Chausmer & Katz, 2002; Gendreau, Gariepy, Petitto &
Lewis, 1997; Heijtz, Beraki, Scott, Aperia & Forssberg, 2002; Reavill, Bond,
Overend & Hunter, 1993). Heijtz et al. (2002), utilizing a range of doses (0.3, 3.0 and
IO mg/kg), showed the biphasic effect SKF has on motor activity in the rat. SKF
appeared to have an initial short inhibition on activity that was then followed by a
longer-lasting increase in activity. The inhibitory period did not appear to involve an
increase in stereotypy. SKF has also been found to increase grooming behavior in the
rodent. In addition to the immediate motor effects of SKF, the DI agonist also
produces immediate autonomic and physiological arousal effects similar to those of
cocaine and amphetamine (Chausmer & Katz, 2002). For example, Reavill et al.
(1993) found that SKF could replace cocaine and amphetamine in drug
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discriminiation studies. Rosenzweig-Lipson and Bergman (1993) found that SKF
acted as a partial substitute for cocaine in rats.
DI receptors are primarily localized post-synaptically, especially in the
striatum, nucleus accumbens, olfactory tubercle and the cerebral cortex (Sibley et al.,
1993). Additionally, these areas have been found to be stimulated with SKF
administration (Reavill et al., 1993; Rosenzweig-Lipson et al., 1993). Heijtz et al.
(2002) suggested that the stimulatory effects of SKF are mediated via the striatum,
whereas the inhibitory effects are mediated via the medial prefrontal cortex.
SKF administration could produce longer term activity patterns similar to
those seen following amphetamine administration. The areas in which DI receptors
are located and that SKF stimulates are involved in the mediation of motor activity.
Consistent with a within system adaptation, the same DI receptors stimulated by
amphetamine in the short term could be involved in the longer term expression of
hypo-activity.

Therefore, SKF could produce hypo-activity 20 hr after

administration.

D2-like agonist: Quinpirole. Quinpirole is a dopamine D2-like receptor
agonist. Andersen and Jansen (1990) showed that Quinpirole has a high affinity for
both D2 and D3 receptors, with a greater affinity for D3 receptors. However,
Quinpirole is regularly used as a D2-Iike receptor agonist.
A number of studies have shown the immediate effects of Quinpirole on
activity in rats (Eilam, Golani & Szechtman, 1989; Eilam & Szechtman, 1989; Van
Hartesveldt, 1997). Eilam and Szechtman (1989) showed the biphasic locomotor
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effects of Quinpirole by administering a range of doses to rats. The researchers found
that moderate to high doses (0.5 - 8 mg/kg) produced an initial inhibition of activity
followed by stimulation of activity that lasted for about 2 hr. Others such as Van
Hartesveldt (1997) showed that Quinpirole was similar in locomotor-activating effect
to apomorphine, a non-selective dopamine agonist. The study found that lower
subcutaneous doses (0.0, 0.02 or 0.2 mg/kg) could also elicit a biphasic activity
profile. However, Quinpirole administration did not produce stereotypy.
Quinpirole appears to produce activity via the striatum and the nucleus
accumbens. Van Hartesveldt, Cottrell, Potter, and Meyer (1992) found that
Quinpirole injected into the striatum but not into the nucleus accumbens produced the
same locomotor effects as a systemic administration. Others such as Mogenson and
Wu (1991) found that injection of Quinpirole into the nucleus accumbens reduced
amphetamine-elicited locomotion. Mogenson and Wu (1991) and Furmidge, Tong,
Petry, and Clark (1991) suggested that the initial inhibitory effects of Quinpirole may
be mediated by DA receptors in the nucleus accumbens, whereas the secondary
stimulatory effects may be due to the striatum. These areas are well known to be
involved in locomotion.
Quinpirole administration could produce longer-term activity patterns similar
to those seen following amphetamine administration. D2 receptor stimulation
produces many of the same behavioral effects as non-selective dopamine agonists,
though not as robustly. Consistent with a within system adaptation, the same D2
receptors stimulated by amphetamine in the short term could be involved in the
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longer term expression of hypo-activity. Therefore, Quinpirole could produce hypoactivity 20 hr after administration.

Method
Subjects
The subjects were 64 male rats of the Wistar strain, purchased from Harlan
(Indianapolis, IN). Prior to the start of the study all rats were housed in pairs in the
departmental colony in a temperature of 20°C - 22°C and on a 12-hr light/ 12-hr dark
cycle. Rats had free access to food (5001 Rodent Diet, Lab Diet) and water, and
weighed between 300 and 400 g at the start of the experiment. Animals were treated
in accordance with ethical guidelines established by the National Institutes of Mental
Health and approved by Morehead State University IACUC.

Apparatus
Sixteen stations were used (see Figure 1). The 16 stations were located in two
well-isolated rooms (each approximately 1.8 m X 2.1 m X 2.6 m high). Within each
room there were eight sound attenuating, wooden compartments (58 cm X 42 cm X
71 cm high, with a shelf 58 cm from the bottom). The interior of each compartment
was white and each compartment had a fan (Sunon, sfl 1580A) mounted in the upper
portion of one side wall for ventilation and to mask out sound. A light fixture (LampiPico accent light, 4-W) was mounted in the middle of the back wall. The lights were
used to produce the same 12-hr light/ 12-hr dark cycle in all stations.
In each compartment was a plastic cubicle (40 cm X 20 cm). The floor of the
cubicle was a black metal pan, which contained a thin layer of micro-waved topsoil to
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Figure 1. Picture of 16 stations used to house and record activity of rats. Plus symbols
indicate software tracking the activity of rats.
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provide absorbency and minimize reflections. The right wall had two· vertical
masonite panels, one of which held a drinking tube (8 cm from the front of the
cubicle and 6 cm from the floor) attached to a 250 ml bottle of water. The other panel
contained an opening (15 cm from the front and 6 cm from the floor) to a feeding bin,
which held 200 g of powdered meal (Lab Diet, Rodent Diet 5001). In the ceiling of
the compartment, and centered 50 cm above the floor of each cubicle, was a
monochrome infrared camera (Super Circuits #DC 12-500R). The lens of the camera
was surrounded with IR-emitting diodes to monitor locomotor activity in the dark. A
paper disk encircled the lens so that direct light could not shine on the floor below.
The cameras were connected by cables to a monochrome multiplexer (RobotDuplex Digital Video Multiplexer, DMV16Q), which combined images from the
cameras in each of the 16 stations into one image for recording and quantification.
The multiplexer was connected to a video recorder (JVC, SR-VlOU), a monitor (14"
Trinitron high resolution video monitor, ECM-1402H), and a computer. The
computer (Dell, M782p) contained a piccolo frame grabber. An EthoVision Pro 3.0
Video Tracking, Motion Analysis and Behavior Recognition System collected and
analyzed the data. Each animal was tracked within an area corresponding to the
dimensions of the floor. The system was programmed to take two samples per
second. The gray scaling method was used in object detection. Control equipment
was located in an adjacent room.
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Drugs

SKF 81297 (0.4 mg/ml and 0.2 mg/ml) (Sigma) was mixed in distilled water.
Quinpirole (0.4 mg/ml and 0.2 mg/ml) (Sigma) was mixed in saline. Amphetamine
(2.0 mg/ml) (Sigma) was mixed in saline. All drugs were injected subcutaneously in
the back of the neck in a volume of 1.0 ml/kg. Saline was the control treatment.
Procedure

The experiment included 6 treatment groups: saline (N= 10), amphetamine
(N=l2), 0.2 Quinpirole (N=l2), 0.4 Quinpirole (N=l2), 0.2 SKF (N=8), and 0.4 SKF
(N=8). The first 4 groups were run in one series of studies, and the last 2 groups were
run in a separate series. Throughout each study rats were continuously housed in one
of the stations in a 12-hr light/ 12-hr dark cycle and allowed free access to food and
water.
Figure 2 displays a schematic diagram of the basic procedure. Up to 2
habituation ("Hab") cycles were run. No treatments were given during habituation
cycles. Rats then received a series of control treatments followed by a series of drug
treatments. All treatments occurred at the start of the light cycle. During the first
control treatment, each rat was removed in turn from its station, weighed and
vigorously rubbed on the back of the neck. During subsequent control treatments
("Saline"), animals also received a subcutaneous injection of saline (0.5 ml) into the
nape of the neck. Control treatments were separated by 48 hr. Control treatments
were given until patterns of activity across groups were similar for 2 consecutive
control-treatment cycles. While a rat was being treated, its apparatus was maintained.

17

Dav Cvcle
1 Hab1

LID cvcle
1 2 3
1/l·H

2

3 Hab2

4

5

6

7

8

9 10 11 1 - - - -

M
HIM

4

5 Saliile1 'IJM
6
7 Saliile2 TIM
B
9 Drua1 TIM

10
11
12 Drua2 TIM
13
I In appar_atus
H Habituation

M

-

I

"'

M
M
M

o·

T
M
0

Treatment
Maintenance
Out of,,apparatus
17 System re·corcling
~Animals handled

Figure 2. Diagram of procedure used in Experiment 1 showing habituation (Hab),
control (Saline), and treatment (Drug) cycles. Lights-on/ lights-off indicated on top
by light and dark boxes. Each row is a day.

18

Maintenance of the apparatus consisted of wiping down the pan, adding new top soil,
and replenishing food and water. Treatment and maintenance took approximately 2
min per station.
Following control treatment cycles, 2 drug treatments cycles were run
("Drug"). Drug treatment cycles were similar to control treatment cycles except that
different groups of rats received different drug treatments. Drug treatments included
saline, 2.0 mg/kg amphetamine, 0.2 mg/kg Quinpirole, 0.4 mg/kg Quinpirole, 0.2
mg/kg SKF 81297, or 0.4 mg/kg SKF 81297. All drugs were injected subcutaneously
into the back of the neck in a volume of 1.0 ml/kg. At least 72 hr elapsed between
drug treatments to allow drug to be cleared from the body. Throughout the study,
monitoring began at the same time in all stations -- at lights on and shortly before
treatments began. Activity of animals was monitored continuously for 33 hr.
Additional station and animal maintenance occurred between treatment cycles, when
animals were not being monitored.
Data Analysis

Tracking software was used to quantify total distance moved for each rat into
10-min bins. Though monitoring began at lights on, for each rat activity was
quantified beginning with the 10-min bin following treatment. Data were then
combined into 33 1-hr bins for each rat. All hourly activity totals were expressed as a
percentage of each rat's mean control value. To obtain this mean for each rat, hours
2-25 were averaged across the last 2 control cycles. Hourly percent control values
were averaged for each rat across these 2 control cycles and across the 2 drug
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treatment cycles. Activity was also averaged into 3-hr bins for each rat. Activity was
then averaged across subjects in a treatment group.
Changes in immediate activity (hours 1-6 post-treatment) and longer-term
activity (hours 7-33 post-treatment averaged into 3-hr bins) were analyzed with an
analysis of variance (ANOVA). One-way between and within ANOVAs were
performed on significant main effects. All significant results were followed-up with
Fisher's PLSD post hoc analysis or paired t-tests.
Results
Immediate results. Figure 3 shows mean activity (as a percentage of control)

for the first 6 hr post-treatment for all 6 groups during the control cycles. Activity
appeared to be elevated for the first hour after treatment and then to decline to normal
levels for hours 2-6 post-treatment. A six (drug treatment groups) by six (posttreatment hours) mixed two-way analysis of variance (ANOVA) was conducted. No
significant effect of group or significant group by hour interaction was obtained, F(5,
56)

= 0.717, p > .05 and F(25, 280) =0.80, p > .05. A significant effect of hour was

obtained, F(5, 280) = 116.206, p < .0001. Fisher's PLSD post hoc analysis indicated
that overall activity was significantly higher during the first hour post-treatment than
during all other hours (p < .0001). No other differences were found.
Figure 4 shows mean activity (as a percentage of control) for the first 6 hr
post-treatment for all 6 groups during the treatment cycles. The amphetamine group
appeared to be elevated in activity through hour 5. All other treatment groups showed
a decline to normal activity levels after the first or second hour. Again, a six (drug
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treatment groups) by six (post-treatment hours) mixed two-way ANOVA was
conducted. Significant effects of group and hour were obtained, as well as a
significant interaction, F(5, 56) = 98.373, p < .0001, F(5, 280) = 114.310, p < .0001
and F(25, 280) = 16.525, p < .0001. Additional analyses were conducted to compare
the activity of groups at each hour and the activity within each group across hours.
First, one-way ANOVAs were conducted between groups at each hour and
additional Fisher's post hoc analyses were conducted to examine significant effects.
Groups differed during the first hour post treatment, F(5, 56) = 38.698, p < .0001.
The amphetamine group was greater in activity than all other groups, ps < .0001, and
both the low and the high dose SKF groups were greater in activity than the
Quinpirole and saline groups, ps < .0005. Groups also differed in the second hour
post-treatment F(5, 56) = 77.181, p < .0001. The amphetamine group was again
greater in activity than all other groups, ps < .0001. The high dose Quinpirole group
(0.4 mg/kg) was significantly greater in activity than the low dose Quinpirole group,
the SKF groups and the saline group, ps < .05. Groups also differed during hours 3
and 4, F(5, 56)

= 45.696 and 7.845, ps = < .0001. During these hours the activity of

only the amphetamine group was elevated, ps < .0001. By hour 6 post-treatment there
were no group differences in activity, ps > .05.
Second, separate one-way within group ANOVAs were conducted for each
treatment group. All groups showed a significant decrease in activity across hours,
F(5, 45) = 18.628, F(5, 55) = 28.125, F(5, 35) = 111.652, F(5, 35) = 547.702, F(5,

55) = 20.521 and F(5, 55) = 60.419, allps < .0001, for saline, amphetamine, 0.2 SKF,

22

-

1500
__._SAL

--A-0,2SKF

E

~

"C

~

....._.o.4SKF
1000

-e-0.2Q
----0.4O

0

:iil:
Cl)

0

C

.iC

500

0

3

6

9

12

15

18

10 min Bin Post-Administration

Figure 5. Mean distance moved in 10-min bins during first 3 hr post-administration
for saline, 0.2 mg SKF, 0.4 mg SKF, 0.2 mg Quinpirole, and 0.4 mg Quinpirole
groups during drug cycles. ± SEM bars are shown.

23

0.4 SKF, 0.2 Quinpirole and 0.4 Quinpirole groups, respectively. For the
amphetamine group, activity declined from hours 1 to 3, 3 to 4 and 4 to 5, ps < .0001.
For the 0.2 SKF group, activity declined from hours 1 to 2, p < .0001. For the 0.4
SKF group, activity declined from hours 1 to 2 and 2 to 3, ps < .0001. For the
Quinpirole groups, activity declined from hours 1 to 2 and 2 to 3, ps < .005 and
.0001. Finally, for the saline group, activity declined from hours 1 to 2, p < .0001.
Figure 5 shows activity (as centimeters moved) in 10-min bins for the first 3
hr post-treatment. The figure shows activity for the 0.2 mg/kg and 0.4 mg/kg SKF,
0.2 mg/kg and 0.4 mg/kg Quinpirole and saline groups. The function for the 0.4
Quinpirole group was biphasic, whereas the functions for the other groups were
monotonically decreasing.
Longer-term effects. Figure 6 shows mean activity (as a percentage of control)

averaged across 3-hr bins for hours 7-33 post-treatment for all 6 groups during the
control cycles. Activity appeared to be lower during the light-period bins than during
the dark-period bins and appeared to be particularly elevated during the last darkperiod bin. A six (drug treatment groups) by nine (post-treatment hour bins) mixed
two-way ANOVA was conducted. No significant effect of group or significant group
by hour interaction was obtained, F(5, 56) = 0.725, p > .05 and F(40, 448) = 1.367, p

> .05. A significant effect of hour was obtained, F(8, 448) = 400.552, p

<.0001.

Fisher's PLSD post hoc analysis indicated that overall activity was significantly
higher during hours 22-24 than at other times and was significantly higher during the
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•

dark-period bins (13-15, 16-18, 19-21 and 22-24 hr bins) compared to the light-period
bins, ps < .0001.
Figure 7 shows mean activity (as a percentage of control) averaged across 3-hr
bins for all 6 groups during the treatment cycles. Again, activity appeared to be lower
during the light-period bins than during the dark-period bins and appeared to be
elevated during the last dark-period bin. However particular groups appeared to differ
during the dark period. Specifically, the activity of the amphetamine group appeared
to decline from the 13-15 hr bin to the 19-21 hr bin. This apparent decline in activity
was not seen in the other groups. Another six (drug treatment groups) by nine (posttreatment hour bins) mixed two-way ANOVA was conducted. No significant effect of
group was obtained, F(5, 56) = 2.230, p > .05. A significant effect of hour and a
significant group by hour interaction were obtained, F(8, 448) = 313.917, p < .0001
and F(40, 448) = 1.518, p < .05.
One-way ANOVAs were conducted between groups at each of the 3-hr darkperiod bins, and additional Fisher's post hoc analyses were conducted to examine
significant effects. Group differences were obtained for the 13-15 hr bin, F(5, 6) =
3.233, p < .05. The amphetamine and two Quinpirole groups displayed less activity
than the saline group, ps < .05. Groups did not differ in activity during the 16-18 hr
bin, F(5, 56) = 2.231, p > .05. However, differences in activity were obtained
between groups during the critical 19-21 hr bin, F(5, 56) = 3.392, p < .01. The
activity of the amphetamine group was found to be significantly less compared to
saline, 0.2 SKF, 0.2 Quinpirole and 0.4 Quinpirole groups during the 19-21 hr bin, ps
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< .05, and trends were obtained for the 0.4 SKF group, p = 0.06. No other differences
between groups were obtained. By the 22-24 hr bin, no differences between groups
were obtained, F(5, 56) = 1.179,p > .05.
Additional, separate one-way within group ANOVAs were conducted for each
treatment group across time. Significant differences were obtained for all groups
across time, F(8, 72) = 35.836, p < .0001, F(8, 88) = 66.06, p < .0001, F(8, 56) =
57.443, p < .0001, F(8, 56)

= 43.177, p < .0001, F(8, 88) = 89.887, p < .0001

and

F(8,88) = 57.519, p < .0001, for saline, amphetamine, 0.2 SKF, 0.4 SKF, 0.2
Quinpirole and 0.4 Quinpirole groups, respectively. For the amphetamine group,
activity declined from the 13-15 hr bin to the 19-21 hr bin. The SKF, Quinpirole and
saline groups did not display significant differences in levels of activity across the 1315, 16-18 and 19-21 hr bins, ps > .05. Activity for all groups was less during the 1315, 16-18 and 19-21 hr bins than during the 22-24 hr bin, ps < .0001. To summarize,
the main difference compared to the control condition was that the amphetamine
treated group first showed a decrease in dark period activity through hours 19-21 and
then showed a normalization of activity afterwards.
Results summary. Figure 8 shows mean activity (as a percentage of control)

for the 19-21 hr bin post-treatment for all 6 groups during the control (left) and
treatment (right) cycles. The amphetamine group alone appeared to decrease in
activity during the 19-21 hr bin from the control cycles to the treatment cycles. A six
(treatment groups) by two (treatment conditions) mixed two-way ANOVA was
conducted. No significant effect of group was obtained, F(5, 56) = 1.557, p > .05. A
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significant effect of treatment and a significant group by treatment interaction were
obtained, F(l, 56) =4.427, p < .05 and F(5, 56) =3.087, p < .05.
To investigate the basis of the interaction, a paired t-test was conducted on the
data for each treatment group. Only the amphetamine group showed a significant
decline in activity from the control to the drug cycles, t(ll)

= 6.547, p < .0001. No

other group differences were obtained, all ps >.05.

Conclusions and Discussion

The purpose of Experiment 1 was to investigate whether stimulation of
dopamine receptor subtypes had the ability to produce hypo-activity 20 hr later. SKF
81297, a selective DI receptor agonist, Quinpirole, a selective D2 receptor agonist,
amphetamine, or saline were administered to rats, and locomotor activity was
monitored for the next 33 hr. If a selective receptor agonist were to produce hypoactivity similar to that produced by amphetamine, then amphetamine might produce
the hypo-activity via that receptor subtype.
Groups did not differ following control treatments. Consequently, the
functions provided a good baseline with which to assess the capacity of the different
drugs to produce significant time- or dose-dependent effects. Drug treatments did
produce differences in activity. During the first few hours post-treatment, the 0.2 and
0.4 SKF, the 0.2 and 0.4 Quinpirole, and the 2.0 mg/kg amphetamine groups
produced very different profiles of immediate period activity. However, the activity
profiles for all drugs were typical for these particular doses. During the longer-term,
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different groups again produced differences in activity patterns. Only the
amphetamine group showed hypo-activity 20 hr post-treatment. Similar to White and
White (in press) our 2.0 mg/kg amphetamine treatment produced a reduction in
activity around hour 20, as well as a recovery in activity shortly afterwards in Wistar
rats. The SKF and Quinpirole treatments did not produce hypo-activity at this time:
Instead these treatments produced a level of activity during the 19-21 hr bin that was
comparable to that produced by saline treatment.
The inability of the selective agonists to produce an activity profile similar to
that produced by amphetamine suggests that amphetamine-induced hypo-activity is
not produced by initial stimulation of either the DI or the D2 receptor subtype alone.
Thus, our hypotheses were not confirmed.
Certain differences in the effects produced by amphetamine and the selective
dopamine agonists probably did not account for the failure of the agonists to produce
hypo-activity. Amphetamine produced hyperactivity in the short-term, but neither
SKF nor Quinpirole did. Conceivably, the initial hyperactivity may have produced
fatigue and later hypo-activity. Neither selective agonist produced hyperactivity, so
there was no fatigue and hypo-activity.
However, some results are inconsistent with this interpretation. 1.0 mg
amphetamine produces a greater amount of short term locomotor activity than a 2.0
mg dose in Wistar rats. However, a 1.0 mg dose does not produce hypo-activity 20 hr
later, whereas a 2.0 mg dose does (White & White, in press). Therefore,
amphetamine-induced hypo-activity does not appear to be due to short term
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hyperactivity that produces a delayed fatigue effect. Similarly, the inability of the
selective agonists to produce short term hyperactivity may not account for their
inability to produce hypo-activity.
Amphetamine and the selective dopamine receptor agonists probably differ in
half life. Some symptoms of amphetamine-induced acute withdrawal might be seen
when amphetamine levels fall to a critical level. For example, low doses of dopamine
agonists activate ventral tegmental area (VTA) auto-receptors and produce catalepsy,
daytime sleepiness, and REM sleep (Fletcher & Starr, 1988; Wanibuchi & Usuda,
1990). Perhaps the selective agonists did not produce hypo-activity near hour 20
because they fell to the critical level with a different time course.
However, a couple of observations are inconsistent with the possibility that
the timing of hypo-activity is related in some simple way to drug half-life. First, the
half-life of amphetamine in rats is about 2 hours, depending on state factors:
Therefore, essentially no drug is present after 20 hr. Second, the timing of hypoactivity seems to be dose independent over a wide rage of doses, from 2.0 mg to 10
mg amphetamine (White & White, 2004). These observations may be more consistent
with a model of amphetamine induced hypo-activity involving short term saturation
of some mechanism. Similarly, the inability of the dopamine agonists to produce
hypo-activity may not have been due to their differences in half-life.
Amphetamine and the selective agonists may also have differed in receptor
activation. SKF and Quinpirole may not have produced hypo-activity, because they
did not produce the same level of short term receptor stimulation that the dose of
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amphetamine did. Ideally I would have wanted to use doses of SKF and Quinpirole
that were comparable to amphetamine in DI or D2 activation. Bringing about this
comparability would be difficult to do, primarily because the modes of action of these
three drugs are very different. Amphetamine is an indirect agonist of dopamine,
whereas SKF and Quinpirole are direct agonists ofDl and D2 receptors, respectively.
The 0.4 doses of both agonists that I used are considered moderately high. By using
this dose I hoped to produce sufficient receptor activation. In a pilot study involving
the same animals, we administered 0.8 mg/kg Quinpirole and again did not observe
hypo-activity 20 hours post-administration. Future studies could use a higher dose
range more systematically.
Finally, selective agonists may not have produced hypo-activity around hour
20 because the cascade of events leading to hypo-activity may be activated by an
initial Dl and D2 receptor interaction. Dopamine Dl and D2 receptors need to be costimulated in order to produce a wide range of dopamine related behaviors, including
locomotion.

Experiment 2: Combined Dopamine Receptor Activation
Hypo-activity 20 hr after amphetamine administration is dependent upon
some sort of initial effect. In Experiment 1, initial stimulation of either D 1 or D2
receptors alone· did not produce this hypo-activity. However, in a prior study,
administration of the non-selective dopamine receptor agonist apomorphine did
(White et al., 2002). The apomorphine result, combined with the results of
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Experiment 1, indicated that initial stimulation of both D1 and D2 receptors may be
necessary to produce hypo-activity. Many immediate dopaminergic effects depend
upon an interaction between D 1 and D2 receptors, and these immediate effects could
produce cascades resulting in longer term effects. Therefore, in Experiment 2, I tried
to determine whether short-term D 1 and D2 receptor co-stimulation could produce
hypo-activity 20 hr later.
To justify this approach, in this section I will review D 1 and D2 receptor
interaction. First, to indicate when an interaction is absent, I will illustrate the concept
of double dissociation and of an additive relation between treatments. Next, I will
explain when an interaction is indicated -- an interaction involves a violation of
double dissociation -- and then I will review the two kinds of synergistic interactions.
Because my dependent measure is activity, I will then outline the evidence that
activity involves an interaction of D 1 and D2 receptors and then describe possible
mechanisms that might be involved. Next, I will review evidence that other behaviors
also depend on a D1 and D2 receptor interaction. Finally, I will describe the evidence
that justifies the particular dose combinations that I chose for Experiment 2.
Hypothesis.

•

Combined dopamine D1 and D2 receptor activation with agonists SKF
81297 and Quinpirole will, in a dose dependent manner, produce
hypo-activity 20-hr post-treatment.
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The ability of the selective agonists (SKF 81297 and Quinpirole) in
combination to produce hypo-activity would support the hypothesis that short term
stimulation by amphetamine of both Dl and D2 dopamine receptor subtypes is
necessary to produce hypo-activity 20 hr later.

Absence of interaction. The double dissociation technique has been used to
provide evidence that different mechanisms are responsible for different processes. In
behavioral pharmacology, a double dissociation would be indicated if agonist and
antagonist manipulations suggested that receptor subtypes made independent
contributions to a particular behavior. The pattern of results in the following
hypothetical example would be consistent with a double dissociation.
1. A control treatment produced a grooming behavior value of 0.

2. Treatment with a Dl agonist produced a grooming behavior value of 4.
3. Treatment with a D2 agonist produced a grooming behavior value of 2.
4. Combined treatment with the D 1 and D2 agonists used above produced a value of
6: This result would be consistent with an additive relationship.
5.

Combined treatment with the Dl agonist and a D2 antagonist produced a

grooming value of 4, that is, the D2 antagonist did not alter the effect of the Dl
agonist.
6.

Combined treatment with the D2 agonist and a D 1 antagonist produced a

grooming value of 2, that is, the D 1 antagonist did not alter the effect of the D2
agonist.
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The pattern of results in this example suggests that DI and D2 receptor
subtypes make independent contributions to the same behavior (grooming).
Interaction. An interaction of receptor subtypes is indicated when agonist and
antagonist manipulations suggest that the effect of one receptor subtype depends on
the co-activation of another receptor subtype. Manipulations that produce exceptions
to the double dissociation rule indicate an interaction. For example, an interaction is
indicated when treatment effects are non-additive or when the effects of stimulating
one receptor subtype are altered synergistically by administering antagonists of a
different receptor subtype. Many dopamine-dependent behaviors, including various
forms of activity, require an interaction of DI and DI receptors.
Types of synergistic interactions. A couple of different types of synergistic
interactions have been defined. A synergistic interaction is present when the effect of
giving receptor subtype agonists in combination is different than the sum of giving
the receptor subtype agonists separately. A synergistic interaction can either be
cooperative or oppositional in nature. A cooperative synergism is present when the
combination produces an effect that is greater than the sum of the agonists given
separately, whereas an oppositional synergism is present when the combination
produces an effect that is smaller.
The following results illustrate the different synergistic interactions by
quantifying stereotypy. A DI agonist treatment produces a stereotypy value of 2. A
D2 agonist treatment produces a stereotypy value of 6. If combined treatment with D 1
and D2 agonists produces a value significantly greater than 8, such as 12, a
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cooperative synergistic interaction has occurred. Alternatively, if combined treatment
with Dl and D2 agonists produces a value significantly less than 8, such as 1, an
oppositional synergistic interaction has occurred.

Interaction and activity. As mentioned, the expression of many dopamine
mediated behaviors requires D 1 and D2 receptor interaction. Various forms of
activity are examples. In a comprehensive review, Waddington (1993) concluded that
motor behavior depended upon D 1 and D2 receptor interaction. Forms of activity
including locomotion, sniffing, jaw movement, stereotypy and turning behavior show
a cooperative synergism when D 1 and D2 agonists are co-administered (Adachi,
Ikeda, Hasegawa, Nakamura, Waddington &

Koshikawa, 1999; Molloy &

Waddington, 1985; Robertson & Robertson, 1986; Starr, 1988). Additionally, Koller
and Herbster (1988) found that Dl agonists combined with D2 agonists elicited levels
of grooming and sniffing that were similar to those elicited by non-selective
dopamine agonists. Combined with the previous findings concerning amphetamine
and apomorphine, these results suggest that longer-term hypo-activity depends on a
short term interaction of DI and D2 receptors.

Interaction and mechanism. Dopamine DI and D2 receptors are found in
many brain regions. Within some neural structures, D 1 and D2 receptors are found
together, while within other neural structures the receptor subtypes are found
separately. Thus, two different hypotheses have been proposed regarding the manner
in which the subtypes interact mechanistically--the co-localization hypothesis and the

neuro-integrative hypothesis.
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The co-localization hypothesis proposes that D 1 and D2 receptors residing on
the membrane of the same neuron interact to produce a particular behavior. Therefore
interaction occurs directly via a unitary mechanism. Studies involving intracerebral
injections into the striatum, nucleus accumbens, ventral striatum, and globus pallidus
have indicated that co-localized Dl and D2 receptors may interact to affect various
measures of activity (Waddington & Daly, 1993). Furthermore, electrophysiological
research has shown that cell firing in the striatum, nucleus accumbens and globus
pallidus may be due to D l/D2 interaction. Guanine nucleotide-binding proteins,
levels of Na+/K+-ATPase activity and arachidonic acid release within the striatum
and nucleus accumbens may also be due to D l/D2 interaction (reviewed in
Waddington & Daly, 1993).
The neuro-integrative hypothesis proposes that Dl and D2 receptors that
reside on distant neurons interact to produce a particular behavior. Therefore

'

interaction occurs indirectly via collaterals or efferents of different neurons
(Robertson & Robertson, 1987). In particular, Dl receptors in the globus pallidus and
the substantia nigra pars reticulata (areas of the basal ganglia involved in motor
output) may interact with D2 receptors in the striatum (although they never specify
which particular nuclei of the striatum). Whether D 1 and D2 interaction within the
striatum is involved in the expression of a particular behavior may depend on the
behavior. The neuro-integrative hypothesis, like the co-localization hypothesis, can
account for regulation of adenylyl cyclase, as well as ascorbic acid release within the
striatum (Waddington & Daly, 1993).
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The co-localization and neuro-integrative hypotheses are still being debated.

Interaction and other behaviors. In addition to activity being affected by
dopamine D 1/D2 receptor interaction, other behaviors and processes also appear to
depend upon an interaction. Dopamine is involved in motor behavior and in reward
and learning processes, thus it is plausible that many behaviors and processes are
influenced by the interaction of D 1 and D2 receptors.
Dopamine receptor interaction modulates arousal and sleep (Ongini, 1993).
D 1 agonists induce EEG arousal and enhance wakefulness, whereas D 1 antagonists
induce sedation and sleep. Furthermore, D2 agonists induce arousal, but D2
antagonists have no effect on sleep. An interaction between DI and D2 receptors may
induce arousal and sedation, but REM sleep appears to be regulated by just D 1
receptors.
Dopamine receptor interaction is involved in aspects of food intake (Cooper &
Al-Naser, 1993). DI receptor agonists do not appear to affect the rate of eating, but
they do reduce the frequency of feeding. Alternatively, D2 receptor agonists appear to
reduce the rate of eating. Moreover, the effects are synergistic when agonists are
combined. An anorectic effect is elicited when DI and D2 receptors are stimulated
simultaneously. This potentiation in food reduction is found with both selective and
nonselective, as well as with direct and indirect, dopamine agents. Furthermore, the
effect also appears to be dose dependent.
On the other hand, drug discrimination does not appear to depend on
dopamine receptor interaction (Nielsen, 1993). D 1 agonists failed to substitute for a
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D2 cue, and, similarly, D2 agonists failed to substitute for a D 1 cue. Different direct
and indirect mixed Dl/D2 agonists could be discriminated (amphetamine,
apomorphine, cocaine). The findings suggested that D 1 and D2 receptors are noninteracting in the drug discrimination model. In other words, a D 1 and D2 interaction
is not necessary for drug discrimination.
The relation between D l/D2 interaction and behavior is complicated. Certain
behaviors depend on simultaneous stimulation of receptor subtypes, whereas others
do not. Furthermore, the effects appear to be dose dependent as well as dependent on
the sensitivity of the behavioral measure.
Interaction and dose issues. The interaction ofDl and D2 receptors appears to

depend upon certain threshold levels of activation for each receptor subtype. Braun
and Chase (1986) suggested that concurrent stimulation of both Dl and D2 receptors
is necessary for the expression of behaviors that are seen with non-selective agonists
such as apomorphine and amphetamine. The study suggested that the nature or the
quality of the behavioral response is a function of the ratio of DI and D2 receptor
stimulation. Furthermore, the response depends upon the level of the underlying DI
receptor tone. The authors suggest that "in order to investigate the dopaminergic
contribution in a particular behavior, one must fix the dose of the D2 stimulation and
use a range of Dl stimulation." Waddington and Daly (1993) also suggested that Dl
receptor stimulation is needed in order to obtain expression of D2 mediated
behaviors. The level of DI tone appears to exert important qualitative and
quantitative synergistic control of D2-stimulated motor activity. That is, increases and
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decreases in D 1 stimulation appear to enhance and attenuate the intensity of D2
agonist-induced behaviors such as stereotypy.
The concept that one receptor subtype gates or enables the function of the
other appears in much of the Dl/D2 interaction literature, although the reason for this
segregation of receptor subtype function is still unclear. Behavioral and physiological
explanations have been given for why a tonic dose is important in D l/D2 interaction.
Waddington (1986, 1993) suggested that the D2 system influences the mode of
expression for a behavior, whereas the D 1 system influences the level of D2 activity.
Thus, Dl receptor stimulation can enhance or block normal behaviors. Similarly,
when a D2 agonist is given, a stereotyped mode of behavior is selected that can then
be either enhanced or blocked by D 1 agonists or antagonists. Waddington also
suggested that the normal level of tonic D 1 activity is high. Other researchers such as
LaHoste and Marshall (1990) suggested that the effects ofDl tonic activation may be
due to interactions with GABA. GABA activity is modulated by Dl receptors in the
substantia nigra pars reticulata (SNr), which in turn influences motor activity. The
only way for a D2 agonist to activate GABA is by first stimulating D 1 receptors in
the SNr. Therefore, the researchers suggested that GABA might regulate D 1 tone and
Dl behavioral influence.
Many dopamine mediated effects depend on threshold doses of agonists and
an appropriate balance of receptor activation. The reason why a tonic dose of D 1
activation is necessary for the expression of behavior is not understood. However, to
increase the likelihood of using a combination that has these properties and to elicit
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hypo-activity around hour 20, I used an increasing dose of SKF in combination with a
fixed, moderately-high dose of Quinpirole.
Methods
Subjects

The subjects were 32 male rats of the Wistar strain, purchased from Harlan
(Indianapolis, IN). As in Experiment 1, prior to the start of the study all rats were
housed in pairs in the departmental colony in a temperature of 20°C - 22°C and on a
12-hr light/ 12-hr dark cycle. Rats had free access to food (5001 Rodent Diet, Lab
Diet) and water and weighted between 300 and 400 g at the start of the experiment.
Animals were treated in accordance with ethical guidelines established by the
National Institutes of Mental Health.
Apparatus

Eight of the sixteen stations used in Experiment 1 were utilized in Experiment
2. The stations were housed in one of the rooms from that experiment. The same
control equipment was used.
Drugs

0.2 mg/ml, 0.4 mg/ml or 0.8 mg/ml SKF 81297 (Sigma) was mixed with 0.4
mg/ml Quinpirole (Sigma) in saline. All drugs were injected subcutaneously in the
back of the neck in a volume of 1.0 ml/kg. Saline was used as the control treatment.
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Procedure

Figure 9 displays a schematic diagram of the basic procedure. Once a day for
3 days prior to the start of each study animals were handled, weighed and vigorously
rubbed on the nape of the neck for several seconds. Each study involved 2 groups run
in the stations during alternating administration cycles. During a typical
administration cycle animals in the first group were taken out of the colony and
placed in individual stations 2 hr prior to lights on. At lights on, each animal was
briefly removed from the station and treated.

Treatment involved subcutaneous

injection into the nape of the neck. After administration, the rat was placed back into
the apparatus where activity could be monitored for the next 33 hr. After 33 hr
animals were removed from the stations and placed back into the departmental
colony. At this time, maintenance of the apparatus occurred. Maintenance consisted
of wiping down each pan, adding new top soil, and replenishing food and water. The
second group was then exposed to the same conditions beginning the next day. All
rats were housed on the same 12-hr light/ 12-hr dark cycle either in the departmental
colony on non-testing days or in the apparatus on testing days. Throughout the
experiment, animals had free access to food and water.
Each group received 2 administration cycles involving control treatments
followed by 2 administration cycles involving drug treatments. Consequently, the 2
groups were alternated in the stations for a total of 4 administration cycles each.
Treatments for a particular group were always separated by at least 96 hr. During the
control treatment cycles all animals were treated with 0.5 ml saline. During the drug
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treatment cycles animals were treated with 1.0 ml/kg of different combinations of
drug. For each group the dose of Quinpirole was fixed, but across groups the dose of
SKF 81297 with which Quinpirole was combined varied. The 4 treatment groups
were 0.0 SKF/ 0.4 Quinpirole, 0.2 SKF/ 0.4 Quinpirole, 0.4 SKF/0.4 Quinpirole, and
0.8 SKF/ 0.4 Quinpirole.
Data Analysis
The tracking software was again used to quantify total distance moved for
each rat into 10-min bins. For each rat activity was quantified beginning with the 10min bin following treatment. Again, data were then combined into 33 1-hr bins for
each rat. Similar to Experiment 1, all hourly activity totals were expressed as a
percentage of each rat's mean control value. Hourly percent control values were then
averaged for each rat across the 2 control cycles and the 2 treatment cycles. Activity
was also averaged into 3-hr bins for each rat. Activity was then averaged across
subjects in a treatment group.
Changes in immediate activity (hours 1-6 post-treatment) and longer-term
activity (hours 7-33 post-treatment averaged into 3-hr bins) were analyzed with
within-subjects analysis of variances (ANOVAs). One-way within subjects ANOVAs
were performed on significant main effects. All significant results were followed-up
with Fisher's PLSD post hoc analyses or paired t-tests.
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Results
Immediate effects. Figure 10 shows mean activity (as a percentage of control)
for the first 6 hr post-treatment for 0.0 SKF/ 0.4 Quinpirole and 0.2 SKF/ 0.4
Quinpirole combination groups during control and drug cycles. Figure 11 shows
similar data for 0.4 SKF/ 0.4 Quinpirole and 0.8 SKF/ 0.4 Quinpirole groups. In order
to evaluate how activity changed from control to drug cycles, a series of analyses
were done on the data for each group. First, to assess overall effects, a two (treatment
condition [control or drug]) by six (post-treatment hour) within subjects two-way
ANOVA was performed ("overall analysis"). Next, to investigate changes in activity
across post-treatment hours, two separate one-way within subjects ANOVAs were
done on control and treatment data ("time analysis"). Fisher's PLSD post hoc analysis
was used to examine significant effects. Finally, to compare activity during control
and drug cycles at each hour post-treatment, six separate within subjects t-tests were
carried out ("condition analysis").

0.0 SKF/ 0.4 Quinpirole group. In the overall analysis no significant effect of
condition was obtained, F(l, 7) = 1.873, p > .05. A significant effect of hour and a
significant condition by hour interaction were obtained, Fs(5, 35) = 15.874 and 4.527,

ps < .0001 and .01. The time analyses showed that, for both control and drug cycles,
activity changed significantly over time, F(5, 35) = 23.638, p < .0001 and F(5, 35) =
8.446, p < .0001. Activity during control cycles was elevated during the first hour
compared to all other hours post-treatment, ps < .0001. Activity during drug cycles
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was elevated during hours 1 and 2 compared to all other hours post-treatment, ps <
.01. The condition analysis showed that activity was elevated during control cycles
relative to drug cycles during hour 5 post treatment, 1(7) = 3.147, p < .05

0.2 SKF/ 0.4 Quinpirole group. In the overall analysis no significant effect of
condition was obtained, F(l, 7) = 0.033, p > .05. A significant effect of hour and a
significant condition by hour interaction were obtained, Fs(5, 35) = 31.149 and
51.805, ps < .0001. According to the time analysis, for control and drug cycles,
activity changed significantly over time, F(5, 35)

= 51.805, p < .0001

and F(5, 35)

=

78.6060, p < .0001. Activity during control cycles was elevated during the first hour
compared to all other hours post-treatment, ps < .0001. Activity during hour 2 was
elevated compared to hours 3, 5 and 6 post-treatment, ps < .05. Furthermore, activity
during hour 4 was elevated compared to hours 3, 5 and 6 post-treatment, ps < .05.
Activity during drug cycles was elevated during the first hour compared to all other
hours post-treatment, ps < .0001. According to the condition analysis, differences in
activity were obtained during hours 1, 3 and 4 post-treatment, ts(?) = -2.379, 2.915
and 3.381, ps < .05. Activity of drug cycles was higher during the first hour, and
activity of control cycles was higher during hours 3 and 4.

0.4 SKF/ 0.4 Quinpirole group. In the overall analysis no significant effect of
condition was obtained, F(l, 7) = 4.074, p > .05. A significant effect of hour and a
significant interaction were obtained, Fs(5, 35) = 53.944 and 2.746, ps < .0001 and
.05. According to the time analysis, for both control and drug cycles, activity changed
significantly over time, F(5, 35) = 11.833, p < 0001 and F(5, 35)
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Activity during control cycles was elevated during the first hour compared to all other
hours post-treatment, ps < .0001. The same was true for drug cycles, ps < .0001.
According to the condition analysis a difference in activity between control and drug
treaiments was obtained during the first hour, when activity of drug cycles was
elevated, t(7) = -3.136, p < .05.
0.8 SKF/ 0.4 Quinpirole group. In the overall analysis no significant effect of

condition was obtained, F(l, 7) = 1.183, p > .05. A significant effect of hour and a
significant interaction were obtained, Fs(5, 35) = 29.260 and 5.026, ps < .0001 and
.01. According to the time analysis, for control and drug cycles, activity changed
significantly over time, F(5, 35) = 18.833, p < .0001 and F(5, 5) = 17.497, p < .0001.
Activity during control cycles was elevated during the first hour compared to all other
hours post-treatment, ps < .0001. The same pattern was obtained during drug cycles,
ps < .0001. According to the condition analysis, a difference in activity was obtained

during hour 3 post-treatment, when activity of control cycles was elevated, t(7) =
2.448, p < .05.
Figure 12 shows activity (as centimeters moved) in 10-min bins for the first 3hr post-treatment. The figure shows activity for each group during drug cycles. All
functions were biphasic. Adding each dose of SKF seemed to partially alleviate the
hour 1 inhibition of activity produced by Quinpirole.
Longer-term effects. Figure 13 shows mean activity (as a percentage of

control) averaged across 3-hr bins for hours 7-33 post treatment for 0.0 SKF/ 0.4
Quinpirole and 0.2 SKF/ 0.4 Quinpirole combination groups during control and drug
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cycles. Figure 14 shows the same data for 0.4 SKF/ 0.4 Quinpirole and 0.8 SKF/ 0.4
Quinpirole groups. In order to evaluate how activity changed from control to drug
cycles, a series of analyses, similar to those done on immediate period activity, were
planned. For the overall analysis a two (treatment condition) by nine (3-hr bin posttreatment) within subjects two-way ANOVA was performed. When a significant
effect of treatment or a significant treatment by bin interaction was obtained, time
analysis and condition analysis were done.

In the time analysis, to investigate

changes in dark-period activity across 3-hr bins, two separate one-way within subjects
ANOVAs were done on control and treatment data. Fisher's PLSD post hoc analyses
were used to interpret significant effects. In the condition analysis, activity for control
and drug cycles was compared at each of the 3-hr dark-period bins with four separate
within subjects t-tests.
0.0 SKF/ 0.4 Quinpirole group. In the overall analysis no significant effect of

condition and no significant condition by hour interaction were obtained, F(l, 7) =
0.469, p > .05 and F(8, 56) = 0.621, p > .05. A significant effect of hour was
obtained, F(8, 56) = 21.143, p < .0001. Fisher's PLSDs were used to interpret the
significant main effect of 3-hr bin. Activity was elevated during dark-period bins
relative to light-period bins, and it was elevated during bin 22-24 relative to other
dark-period bins, ps < .05.
0:2 SKF/ 0.4 Quinpirole group. The same pattern of results was seen. In the

overall analysis no significant effect of condition and no significant interaction of
condition and 3-hr bin were obtained, F(l, 7) = 0.484, p > .05 and F(8, 56) = 1.787, p

•
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> .05. A significant effect of hour was obtained, F(8, 56) = 32.366, p < .0001. Again,
activity was elevated during dark-period bins relative to light-period bins, and it was
elevated during bin 22-24 relative to other dark-period bins, ps < .05.

0.4 SKF/ 0.4 Quinpirole group. In the overall analysis no significant effect of
condition was obtained, F(l, 7) = 1.939, p > .05. A significant effect of 3-hr bin and a
significant condition by 3-hr bin interaction were obtained, Fs(8, 56) = 145.688 and
9.562, ps < .0001. In the time analysis, for control and drug cycles, activity changed
significantly over time, F(8, 56)

= 83.748, p

< .0001 and F(8, 56)

= 90.518, p

<

.0001. For control cycles activity was elevated during the 13-15 hr bin compared to
the 16-18, 19-21 and 22-24 hr bins, ps < .01. For drug cycles, activity was elevated
during the 13-15 hr bin compared to the 16-18 and 19-21 hr bins, ps < .05 and .001.
Activity was also elevated during the 22-24 hr bin compared to all other dark period
bins, ps < .0001. According to the condition analysis, compared to control, drug cycle
activity was lower during the 13-15, 16-18 and 19-21 hr bins, ts(7) = 2.858, 2.60 and
4.247, ps < .05 - .01, and higher during the 22-24 hr bin, t(7) = -3.367, p < .05. To
summarize, during the drug condition activity appeared to decline during the 19-21 hr
bin and to rebound during the 22-24 hr bin

0.8 SKF/ 0.4 Quinpirole group. According to the overall analysis no
significant effect of condition was obtained, F(l, 7) = 0.246, p > .05. A significant
effect of 3-hr bin and a significant interaction of condition and 3-hr bin were
obtained, Fs(8, 56) = 75.277 and 8.102, ps < .0001. According to the condition
analysis, for both control and drug cycles, activity changed significantly over time,
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F(8, 56)

= 69.927, p < .0001

and F(8, 56)

= 42.415, p < .0001. For control cycles

activity was elevated during the 13-15 hr bin compared to the 16-18 and 22-24 hr
bins, ps < .05 and .01. Additionally, activity was elevated during the 19-21 hr bin
compared to the 16-18 and 22-24 hr bins, ps < .05 and .001. For drug cycles, activity
was elevated during the 22-24 hr bin compared to all other dark period bins, ps <
.005. The condition analysis indicated that activity was lower during drug cycles
compared to control cycles during the 13-15 and 19-21 hr bins, ts(7) = 4.229 and
3.196, ps < .01 and .05. Activity then increased during drug cycles compared to
control cycles during the 22-24 hr bin, t(7) = -2.433, p < .05.
Results summary. Figure 15 shows activity for all combination groups during

the 19-21 hr bin post-treatment. Drug data were expressed as a percentage of control
for each subject, and t-tests were used to see if groups' means were significantly
different from 100%. The 2 high dose combination groups had decreased activity
during the 19-21 hour hr bin, ts(7) = -4.510 and -3.137, ps < .01 and .05, whereas the
2 low dose combination groups did not, ts(7) = -0.333 and 0.171,ps > .05.

Conclusions and Discussion

The purpose of Experiment 2 was to investigate whether co-stimulating D 1
and D2 receptor subtypes had the ability to produce hypo-activity 20 hr later. A range
of doses of the D 1 agonist SKF 81297 was combined with a dose of the D2 agonist
Quinpirole. Different groups of rats were given 0.0 SKF/ 0.4 Quinpirole, 0.2 SKF/ 0.4
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Quinpirole, 0.4 SKF/ 0.4 Quinpirole or 0.8 SKF/ 0.4 Quinpirole, and activity was
then monitored for 33 hr. The ability of combined agonists to produce hypo-activity
would be consistent with the possibility that concurrent stimulation of D1 and D2
receptors induces amphetamine-induced hypo-activity.
With respect to short term effects, only the 0.0 SKF/ 0.4 Quinpirole treatment
group showed an effect of drug on activity through hour 2 post-administration. The
function for this combination group was biphasic, which is typical of a 0.4 mg/kg
dose of Quinpirole. The other three combination groups (0.2 SKF/ 0.4 Quinpirole, 0.4
SKF/ 0.4 Quinpirole and 0.8 SKF/ 0.4 Quinpirole) had a high level of activity only
during the first hour post-treatment
Groups showed different patterns of longer term activity following treatment
compared to control. Specifically, the two lower dose combination groups (0.0 SKF/
0.4 Quinpirole and 0.2 SKF/ 0.4 Quinpirole) did not display hypo-activity during the
19-21 hr bin. However, the two higher dose combination groups (0.4 SKF/ 0.4
Quinpirole and 0.8 SKF/ 0.4 Quinpirole) did display such hypo-activity. Additionally,
during drug cycles the two higher dose combination groups also showed levels of
activity that were elevated during the 25-27 hr bin. This pattern of hypo-activity
around hour 20 and of enhanced activity near hour 25 is very similar to the activity
pattern seen following amphetamine administration. These results obtained with the
high dose combination groups suggest that amphetamine-induced hypo-activity may
require initial co-activation of D 1 and D2 receptors. Additionally, the inability of the
0.2 SKF/ 0.4 Quinpirole combination to produce hypo-activity suggests that this
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behavior is dependent not only on co-activation, but also on dose or amount of
receptor stimulation.
Interestingly, these data from Experiment 2 suggest that an oppositional
interaction in the short-term may be correlated with hypo-activity in the longer-term.
Compared to the Quinpirole-alone group, the 0.4 SKF/ 0.4 Quinpirole group had a
higher initial level of activity. The function for this dose combination had an earlier
asymptote and a quicker decline to zero. I will have more to say about the
implications of short term receptor interaction in the general discussion when I make
comparisons across experiments.
The results of Experiment 2 provide further evidence regarding the processes
and mechanisms that might be responsible for amphetamine-induced hypo-activity.
The high dose treatment combinations did not produce levels of immediate
activity like that of amphetamine. The levels of activity produced by these
combinations might not be expected to produce fatigue. And yet, like amphetamine,
these combinations did produce longer-term hypo-activity. Thus, amphetamineinduced hypo-activity may not be due to a fatigue effect.
The pharmacokinetic profiles of the agonists used in this research are not
known. Given the nature of their short term effects on activity, they probably have
short half-lives that are very different from one another and from the half-life of
amphetamine. The fact that both the combined agonists and amphetamine can
produce hypo-activity 20 hr after administration provides further evidence that
expression of hypo-activity is not related to drug half-life.
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In Wistar rats, 2.0 mg/kg amphetamine is needed to produce hypo-activity 20
hr after administration. In the present experiment, the 0.4 SKF/ 0.4 Quinpirole
combination produced a similar effect. Perhaps amphetamine produces hypo-activity
when it brings about a level of DI and D2 receptor activation that is similar to that
produced by a 0.4 SKF/ 0.4 Quinpirole dose combination.

General Discussion

Amphetamine administration produces hypo-activity 20 hr later in rats (White
et al., 2004; White & White, in press). The purpose of this research was to investigate
whether specific dopaminergic mechanisms might contribute to this amphetamineinduced effect. Two experiments were conducted in order to carry out this purpose.
The locomotor activity of rats was recorded after administration of drug. SKF 81297
and Quinpirole, D 1 and D2 receptor agonists, respectively, were administered. In
Experiment 1, dopamine receptor subtype agonists administered alone did not
produce hypo-activity 20 hr later. In Experiment 2, the dopamine agonists
administered in combination did produce such hypo-activity. Co-stimulating DI and
D2 receptors produced a longer-term activity pattern that was similar to that produced
by amphetamine administration.
An oppositional interaction reflected in short-term activity may be correlated
with hypo-activity in the longer-term. Less short term activity occurred following the
0.4 SKF/ 0.4 Quinpirole combination (Experiment 2, Figure 12) than would be
expected by summing the effects of the agonists given separately (Experiment 1,
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Figure 16. Activity during first 3 hr post-administration in 3 min bins for 0.4 mg SKF
and 0.4 mg Quinpirole groups from Experiment I and 0.4 mg SKF/ 0.4 mg
Quinpirole group from Experiment 2 during drug cycles.
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Figure 5). The relevant data are re-plotted in Figure 16. The figure shows centimeters
moved every 10 min following treatment with 0.4 mg/kg SKF, 0.4 mg/kg Quinpirole,
or the combination. The fact that short term D 1/ D2 synergism might have longer
term consequences for behavior seems to be a novel finding. The functions in Figure
16 were from different experiments entailing different methods, so conclusions are
tentative.
As of now, the location of the mechanism involved in the induction of hypoactivity is not known. This research suggests that the location is an area where the
dopamine receptor subtypes converge. Furthermore, the area of convergence may be
involved in motor control. Potential areas include the nucleus accumbens, striatum,
cingulate gyrus and substantia nigra.
Treatments that produce hypo-activity in the longer term produce enhanced
activity in the short term. Opponent process theory provides one explanation for this
reversal in measure. According to opponent process theory, a treatment that produces
an intense state later produces a rebound state having many of the opposite
characteristics. Amphetamine treatment produces an intense state characterized by
hyperactivity and hedonic effects. The hypo-activity observed later may reflect a
rebound state having the opposite characteristics, that is, it may indicate the presence
of a "crash" or acute withdrawal.
According to the theory, the initial response to drug would produce neuroadaptations that outlast the initial drug response and that mediate this crash. In the
case of amphetamine, the initial response and the neuro-adaptations might occur in
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the reward system and involve dopamine. The processes of within system adaptation
and between systems adaptation suggest further details.

In a within system adaptation overlapping mechanisms mediate the initial
state and the rebound state. In Experiment 2, higher dose combinations produced
increased activity in the shorter term and hypo-activity in the longer term. This result
may have reflected a within system adaptation. For example, the site of D 1 and D2
receptor convergence may have contributed to both short term hyperactivity and
longer term hypo-activity. In this case, the short term Dl and D2 receptor synergism
with respect to activity might not just be correlated with later hypo-activity but may
be causally related to it. Amphetamine may produce hypo-activity via such a within
system adaptation.
Alternatively, higher dose combinations may have induced hypo-activity via a
between systems adaptation. In a between systems adaptation different mechanisms
mediate the initial state and the rebound state. For example, the initial state produced
by the higher dose combinations in Experiment 2, and indicated by hyperactivity,
may have been mediated by the reward system. On the other hand, the rebound state,
indicated by hypo-activity, may have been mediated by the sleep system.
Amphetamine and apomorphine have both been shown to produce hypoactivity 20 hr post-administration. The results of this research suggest that Dl and D2
receptor co-activation may be necessary to induce this effect. Several symptoms of
acute withdrawal are present 20 hr after amphetamine receipt, including a
Haloperidol-like cue state, decreased motivation to obtain natural reward, REM sleep
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rebound and hypothermia (Barr & Phillips, 1992; Barret et al., 1992; Edgar & Seidel,
1997; Eikelboom & Stewart, 1981). Whether D1 and D2 receptor co-activation is
necessary to produce these symptoms is unknown. Hypo-activity may be a correlate
of acute withdrawal.

If hypo-activity is indeed an indicator of acute withdrawal, then the methods
used here may provide a convenient animal model with which to study the
determinants of this state.
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